FACTANKER

US-Listed In Vitro & In Vivo Diagnostic Substances — EBITDA Margin Percentiles, FY 2025

Population: 10 US-listed companies (SIC 2835), fiscal year 2025; fiscal year ends 2025-12-28 to 2026-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile-306.7%
25th percentile-73.6%
Median-21.9%
75th percentile14.7%
90th percentile25.7%
Mean-98.9%
Minimum-637.2%
Maximum35.0%
Methodology & sources
EBITDA margin = (operating income + depreciation & amortization) / revenue, all values as filed; computed in SQL per company, then percentiles. Fiscal year 2025 = fiscal years ending 2025-06-01 to 2026-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-02.

Evidence samples

Latest EBITDA Margin percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/ebitda-margin/2025